Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?

Cancer

Volumn 116, Issue 22, 2010, Pages 5290-5296

  Mihu, Coralia N ^a   Kassis, Christelle ^b   Ramos, Elizabeth R ^b   Jiang, Ying ^a   Hachem, Ray Y ^a   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

aspergillosis; combination; echinocandins; liposomal amphotericin B; refractory

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPOFUNGIN; CREATININE; ECHINOCANDIN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASPERGILLUS; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CHILD; CHRONIC LEUKEMIA; CREATININE BLOOD LEVEL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOTHERAPY; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOMA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 78449312315     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25312     Document Type: Article

References (20)

1. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA,. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984; 100: 345-351.
2. Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ,. Causes of death in adults with acute leukemia. Medicine (Baltimore). 1976; 55: 259-268.
3. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992; 11: 99-109.
4. Marr KA, Carter RA, Crippa F, Wald A, Corey L,. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002; 34: 909-917.
5. Denning DW,. Echinocandins and pneumocandins-a new antifungal class with a novel mode of action. J Antimicrob Chemother. 1997; 40: 611-614.
6. Wagner C, Graninger W, Presterl E, Joukhadar C,. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology. 2006; 78: 161-177.
7. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH,. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002; 46: 245-247.
8. Clemons KV, Espiritu M, Parmar R, Stevens DA,. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother. 2005; 49: 4867-4875.
9. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003; 97: 1025-1032.
10. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006; 107: 2888-2897.
11. Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007; 110: 2740-2746.
12. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003; 98: 292-299.
13. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46: 1813-1821.
14. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998; 103: 205-212.
15. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother. 2001; 45: 3474-3481.
16. Hohl TM, Feldmesser M, Perlin DS, Pamer EG,. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis. 2008; 198: 176-185.
17. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis. 2008; 198: 186-192.
18. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004; 39: 1563-1571.
19. Sachs UJ, Reiter A, Walter T, Bein G, Woessmann W,. Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections. Transfusion. 2006; 46: 1909-1914.
20. Safdar A, Rodriguez GH, Lichtiger B, et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006; 106: 2664-2671.